

1 **Real-world outcomes of individualized targeted therapy with insulin glargine**  
2 **300 units/mL in insulin-naïve Korean people with type 2 diabetes: TOBE study**

3

4 Eun-Gyoung Hong<sup>1</sup>, Kyung-Wan Min<sup>2</sup>, Jung Soo Lim<sup>3</sup>, Kyu-Jeung Ahn<sup>4</sup>, Chul Woo Ahn<sup>5</sup>,  
5 Jae-Myung Yu<sup>6</sup>, Hye-Soon Kim<sup>7</sup>, Hyun Jin Kim<sup>8</sup>, Won Kim<sup>9</sup>, Dong Han Kim<sup>9</sup>, Hak Chul  
6 Jang<sup>10</sup>

7

8 <sup>1</sup>Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital,  
9 Hallym University College of Medicine, Hwaseong, South Korea

10 <sup>2</sup>Department of Internal Medicine, Eulji General Hospital, Eulji University School of  
11 Medicine, Daejeon, South Korea

12 <sup>3</sup>Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University  
13 Wonju College of Medicine, Wonju, South Korea

14 <sup>4</sup>Division of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong,  
15 Kyung Hee University School of Medicine, Seoul, South Korea

16 <sup>5</sup>Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University  
17 College of Medicine, Seoul, South Korea

18 <sup>6</sup>Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital,  
19 Hallym University College of Medicine, Seoul, South Korea

20 <sup>7</sup>Division of Endocrinology, Department of Internal Medicine, Keimyung University  
21 School of Medicine, Daegu, South Korea

22 <sup>8</sup>Department of Internal Medicine, Chungnam National University Hospital, Chungnam  
23 National University College of Medicine, Daejeon, South Korea

24 <sup>9</sup>Medical Department, Sanofi Korea, Seoul, South Korea

25 <sup>10</sup>Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul

26 National University College of Medicine, Seongnam, South Korea

27

28 Corresponding author:

29 Hak Chul Jang MD, PhD

30 Department of Internal Medicine, SNU Bundang Hospital

31 Seoul National University College of Medicine

32 82, Gumi-ro, 173-beon-gil, Bundang-gu, Seongnam-si

33 Gyeonggi-do, 13620, South Korea

34 E-mail: janghak@snu.ac.kr

35

36 **Supplementary files**37 **Table S1 Institutional Review Board of the study with their reference numbers**


#	Institutional Review Board (IRB)	IRB ID
1	Kyung Hee University Hospital at Gangdong Institutional Review Board	KHNMC 2016-05-005
2	Keimyung University Dongsan Hospital Institutional Review Board	DSMC 2016-04-040-001
3	Keimyung University Dongsan Hospital Institutional Review Board	DSMC 2016-04-041
4	Inje University Busan Paik Hospital Institutional Review Board	16-0121
5	Dankook University Hospital Institutional Review Board	2016-06-012-021
6	Seoul National University Bundang Hospital Institutional Review Board	B-1607-356-302
7	Myongji Hospital Institutional Review Board	2016-01-067
8	Wonju Severance Christian Hospital Institutional Review Board	2019-03-0138
9	Wonju Severance Christian Hospital Institutional Review Board	2016-06-0012
10	Gachon University Gil Medical Center Institutional Review Board	GAIRB2016-251
11	Ajou University Hospital Institutional Review Board	AJIRB-MED-OBS-16
12	Hallym University Kangnam Sacred Heart Hospital Institutional Review Board	HKS 2016-09-125-014
13	Hallym University Dongtan Sacred Heart Hospital Institutional Review Board	HDT 2016-09-412-007
14	Gangnam Severance Hospital Institutional Review Board	3-2016-0265
15	The Catholic University of Korea St. Vincent's Hospital Institutional Review Board	VC16MSME0244
16	The Catholic University of Korea Seoul St. Mary's Hospital Institutional Review Board	KC16MSME1037
17	Pusan National University Hospital Institutional Review Board	1701-005-061
18	Busan St. Mary's Hospital Institutional Review Board	BSM2017-01
19	Kosin University Gospel Hospital Institutional Review Board	2016-12-013
20	Chuncheon Sacred Heart Hospital Institutional Review Board	2017-01-004
21	Ulsan University Hospital Institutional Review Board	2017-02-003-031
22	Chungnam National University Hospital Institutional Review Board	2017-02-023
23	Soon Chun Hyang University Hospital Institutional Review Board	2017-02-016-009
24	Kyungpook National University Chilgok Hospital Institutional Review Board	2017-03-011

25	Inje University Seoul Paik Hospital Institutional Review Board	2017-03-007
26	Dongguk University Ilsan Hospital Institutional Review Board	2017-01-059
27	Inje University Ilsan Paik Hospital Institutional Review Board	2017-04-027
28	The Catholic University of Korea Incheon St. Mary's Hospital Institutional Review Board	OC17OODI0094
29	Daejeon Eulji Medical Center Institutional Review Board	2017-09-022

39 **FIGURE S1** Participants disposition

40

41



42

43 Abbreviation: HbA1c, glycated hemoglobin.

44

45 **TABLE S2** General baseline demographics and clinical characteristics (full analysis set) of groups

46

Variable	Individualized	General	<i>P</i> value <sup>a</sup>	Total (N = 369)
	target group (n = 88)	target group (n = 281)		
Age, years	61.9 ± 11.3	59.7 ± 11.4	0.0910	60.2 ± 11.4
Male sex, n (%)	58 (65.9)	149 (53.0)	0.0336 <sup>a</sup>	207 (56.1)
Duration of T2DM, years	11.8 ± 8.4	12.4 ± 7.6	0.3165	12.3 ± 7.8
Body weight, kg	66.9 ± 11.5	65.3 ± 11.6	0.1237	65.7 ± 11.5
Body mass index, kg/m <sup>2</sup>	24.9 ± 3.7	24.9 ± 3.5	0.9463	24.9 ± 3.5
HbA1c, %	9.8 ± 1.7	9.9 ± 1.6	0.3066	9.9 ± 1.6
Number of prior diabetic medications, n (%)				
1	17 (19.3)	57 (20.3)		74 (20.1)
2	37 (42.1)	125 (44.5)		162 (43.9)
3	34 (38.6)	99 (35.2)		133 (36.0)

Diabetes complication <sup>b</sup> , n (%)	18 (20.5)	109 (38.8)	0.0016	127 (34.4)
Comorbidity <sup>c</sup> , n (%)	81 (92.1)	264 (94.0)	0.5272	345 (93.5)
Severe hypoglycemia within previous 6 months	1 (1.1)	2 (0.7)	0.5595	3 (0.8)

---

47 *Note:* Values are presented as number (%) or mean ± standard deviation.

48 Abbreviations: HbA1c, glycated hemoglobin; T2DM, type 2 diabetes mellitus.

49 <sup>a</sup>*P* value calculated by comparing individualized and general HbA1c target groups; *P* <0.05. There was no statistically significant  
50 difference except for Male sex, n (%)

51 <sup>b</sup>Participants with at least one diabetes complication.

52 <sup>c</sup>Participants with at least one comorbidity.

53 *P* value calculated by comparing in each group participants achieving and not achieving target.

54

55 **TABLE S3**    **Change in proportion of participants taking concomitant diabetic medications before and after Gla-300**  
 56 **treatment**

Drug class	Individualized target group			General target group			<i>P</i> value <sup>b</sup>	Total population		
	(n = 88)			(n = 281)				(N = 369)		
	Before	After	Change	Before	After	Change		Before	After	Change
Metformin	84.1	83.0	-1.1	80.8	77.6	-3.2	0.4412	81.6	78.9	-2.7
DPP-4i	77.3	71.6	-5.7	69.8	67.3	-2.5	0.4397	71.5	68.3	-3.3
SU	60.2	33.0	-27.3	65.5	45.6	-19.9	0.2988	64.2	42.5	-21.7
SGT2i	2.3	2.3	0	8.5	7.1	-1.4	0.1493	7.0	6.0	-1.1
TZD	14.8	8.0	-6.8	11.4	5.7	-5.7	0.5778	12.2	6.2	-6.0
AGi	2.3	2.3	0	1.1	1.4	0.4	0.6760	1.4	1.6	0.3
Others <sup>a</sup>	0.0	5.7	5.7	1.4	11.7	10.3	NC <sup>c</sup>	1.1	10.3	9.2

57 Abbreviations: AGi; alpha-glucosidase inhibitor; DPP-4i, dipeptidyl peptidase-4 inhibitor; Gla-300, insulin glargine 300

58 Units/mL; SGLT2i, sodium glucose cotransporter-2 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione; NC, Not Calculated.

59 <sup>a</sup>Glucagon-like peptide-1 receptor agonist, short-acting insulin, premixed insulin, meglitinide. <sup>b</sup>Test for between-group difference



60 (individualized versus general HbA1c target group) using generalized estimating equation method. †Not calculated because one  
61 of the variables contained 0.